CytomX Therapeutics, Inc.
NASDAQ:CTMXBiotechnology
-$0.03 today
- Market cap
- $409.85M
- Beta
- 2.09
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$0.33
Volume 4.39M
Average 4.99M
CTMX EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
CytomX Therapeutics, Inc.NASDAQ: CTMX
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA turns negative
Q1 FY2026 EBITDA was -$17.94M, compared with $23.97M a year earlier. Trailing-twelve-month EBITDA was -$57.67M.
Context
- EBITDA amounted to 20.7% of revenue in FY2025, down 3.8 pp from a year earlier.
- EBITDA increased in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 5 analysts of -$52.64M (-234.1%) for the fiscal year ending Dec 2026, a slowdown from the -146.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$17.94M+30.9% QoQ
- Last fiscal yearDec 2025
- -$15.75M-146.5% YoY
- LTMMar 2026
- -$57.67M-232.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -174.8% | -6678.6% | -6503.8 pp |
| 1 year | -146.5% | -234.1% | -87.6 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (15.75M) USD
- Year-over-year change
- -146.5%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (15.75M) | -146.5% |
| FY2024 | 2024-12-31 | 33.86M | +515.9% |
| FY2023 | 2023-12-31 | 5.5M | +105.7% |
| FY2022 | 2022-12-31 | (96.87M) | +14.4% |
| FY2021 | 2021-12-31 | (113.16M) | — |
EBITDA vs competitors
How CTMX compares with its peers on the latest reported figures
- CTMX's LTM Mar 2026 EBITDA of -$57.67M is the 5th highest of the 10 companies compared; the peer median is -$75.93M.
- Its year-over-year change of -232.5% is the lowest of 9, against a peer median of +7.1%.
- EBITDA amounts to 162.2% of revenue for CTMX, versus a peer median of 106.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Aug 2026 | $322.61M | +243.1% | — | 46.0% | |
| LTM Sep 2026 | $57.08M | +205.8% | — | 21.5% | |
| LTM Jun 2024 | -$36.06M | — | — | 4420.7% | |
| LTM Mar 2026 | -$50.64M | -7.0% | — | 32.2% | |
| LTM Mar 2026 | -$57.67M | -232.5% | — | 162.2% | |
| LTM Mar 2026 | -$75.93M | +0.5% | — | 547.9% | |
| LTM Mar 2026 | -$83.2M | +13.7% | — | 105.1% | |
| LTM Mar 2026 | -$106.12M | +42.0% | — | 106.5% | |
| LTM Jun 2026 | -$123.6M | -14.3% | — | 117.7% | |
| LTM Sep 2026 | -$305.37M | -38.1% | — | 272652.7% | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding CTMX) | -$75.93M | +7.1% | — | 106.5% | |
Competitors are the stored peer set for CTMX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 37.31M | 53.16M | 101.21M | 138.1M | 76.2M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 37.31M | 53.16M | 101.21M | 138.1M | 76.2M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 114.19M | 111.65M | 77.68M | 83.38M | 68.73M |
| Selling, General & Admin | 39.16M | 42.85M | 30.02M | 29.73M | 29.84M |
| Operating Expenses | 153.35M | 154.5M | 107.7M | 113.11M | 98.57M |
| Depreciation & Amortization | 2.71M | 2.44M | 2.18M | 1.77M | 1.38M |
| EBITDA | (113.16M) | (96.87M) | 5.5M | 33.86M | (15.75M) |
| EBITDA Margin | -303.3% | -182.2% | 5.4% | 24.5% | -20.7% |
| Operating Income | (116.04M) | (101.34M) | (6.48M) | 25M | (22.36M) |
| Operating Margin | -311.0% | -190.6% | -6.4% | 18.1% | -29.3% |
| Interest Income | 255K | 1.68M | 9.84M | 7.14M | 5.21M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 172K | 2.02M | 9.81M | 7.1M | 5.23M |
| Income Before Tax | (115.87M) | (99.32M) | 3.32M | 32.09M | (17.13M) |
| Pre-Tax Margin | -310.5% | -186.8% | 3.3% | 23.2% | -22.5% |
| Income Tax Expense | 0 | 0 | 3.89M | 224K | 238K |
| Net Income | (115.87M) | (99.32M) | (569K) | 31.87M | (17.37M) |
| Net Margin | -310.5% | -186.8% | -0.6% | 23.1% | -22.8% |
| EPS (Basic) | (1.26) | (1.48) | (0.01) | 0.38 | (0.15) |
| EPS (Diluted) | (1.26) | (1.48) | (0.01) | 0.38 | (0.15) |
| Weighted Avg Shares | 64.15M | 65.74M | 73.81M | 84.44M | 137.94M |
| Weighted Avg Shares (Diluted) | 64.15M | 65.74M | 73.81M | 84.75M | 137.94M |
CytomX Therapeutics, Inc.
NASDAQ:CTMX
Intrinsic Alpha fair value
Locked
Current Price
$1.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.